


HF-POLARIS

zenagamtide | effects on heart failure outcomes in people with obesity

National Data Package



National Leader:




Kasper Rossing

Participant overview

Participant overview	Overall recruitment target	Participants screened	Participants randomised	Screen failure rate*	Off treatment
	N	N	N	%	N
Denmark	90	19	9	37	0
Global	5,610	1,064	438	46	12

*Forecasted

Participants randomised and recruitment target in Denmark in 2026



Screen failure reasons

Screen failure reasons	Denmark	Global*
	N (%)	N (%)
NT-proBNP (I7)	2 (29)	153 (38)
HF decompensation/ eGFR/UACR (I8)	3 (43)	104 (26)
Investigator discretion (E31)	0 (0)	22 (5)
HbA _{1c} >10% (E12)	0 (0)	12 (3)
LVEF (I5)	0 (0)	12 (3)
Diabetic retinopathy (E10)	0 (0)	10 (3)
ICF process (I1)	0 (0)	8 (2)
BMI (I3)	0 (0)	8 (2)
Malignancy history (E22)	1 (14)	7 (2)
Insulin therapy (E11)	0 (0)	6 (2)
Other	1 (14)	64 (16)

*Globally, 34 participants (13%) failed due to more than one eligibility criteria

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated haemoglobin; HF, heart failure; ICF, Informed Consent Form; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide.

Site-level data



Planned number of sites: 9

Site*	PI	Participants, N			
		Screened	In screening	Screen failed	Randomised
2301	Kasper Rossing	1	1	0	0
2302	Morten Schou	2	0	1	1
2303	Jens Hove	3	0	2	1
2304	Søren Auscher	4	0	2	2
2305	Christian Tuxen	2	0	0	2
2306	Peter Bisgaard Stæhr	1	1	0	0
2307	Morten Lindhardt	2	1	1	0
2308	Malene Hollingdal	3	0	1	2
2309	Yongzhong Wang	1	0	0	1

*Only sites that have actively started recruitment are included

Notes



Notes

What are the challenges you face or anticipate facing concerning:



Recruitment?



Retention?



Collaboration with other stakeholders?

Are there any challenges in other areas that you'd like to address in your action plan?

What actions or initiatives can you implement to help resolve these issues?
